
NYSE:ARDT
This summary was created by AI, based on 2 opinions in the last 12 months.
Ardent Healthcare Partners Inc. (ARDT) has seen mixed opinions from experts recently. The latest advice from Michael O'Reilly indicates a cautious approach, following a previous recommendation that has now triggered a stop loss at $10.50, leading to an estimated investment loss of 18%. Despite this setback, O'Reilly remains optimistic about the company's growth potential, particularly with the addition of 18 new urgent care clinics in 2025. With an attractive valuation at 7 times earnings and a return on equity (ROE) of 25%, there is still an anticipated upside of 28%, aiming for a target price of $17.00. Analysts have set a price target of $19.08, suggesting a belief in future growth, but investors are advised to manage their positions carefully amid current challenges.
Ardent Healthcare Partners Inc. is a American stock, trading under the symbol ARDT (previously ARDT-N on Stockchase) on the New York Stock Exchange (ARDT). It is usually referred to as NYSE:ARDT or ARDT
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on ARDT (previously ARDT-N on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for Ardent Healthcare Partners Inc..
Ardent Healthcare Partners Inc. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-11-13. Read the latest stock experts ratings for Ardent Healthcare Partners Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Ardent Healthcare Partners Inc..
Ardent Healthcare Partners Inc. is followed by 12 investors on Stockchase and is a trending stock that is worth watching.
On 2026-09-04, Ardent Healthcare Partners Inc. (ARDT) stock closed at a price of $10.91.
Our PAST TOP PICK with ARDT has triggered its stop at $10.50. To remain disciplined, we recommend covering the position at this time. When combined with previous guidance, this will result in a net investment loss of 18%.